Trade Report: The Citigroup Inc. Begins Coverage on Calithera Biosciences Inc. (CALA)

The Citigroup Inc. Begins Coverage on Calithera Biosciences Inc. (CALA)

Citigroup Inc. initiated coverage on shares of Calithera Biosciences Inc. (NASDAQ:CALA) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Shares of Calithera Biosciences (NASDAQ:CALA) opened at 2.85 on Tuesday. The stock has a 50 day moving average of $3.04 and a 200-day moving average of $3.87. The company’s market cap is $55.54 million. Calithera Biosciences has a 12 month low of $2.20 and a 12 month high of $10.90.

Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. Equities analysts forecast that Calithera Biosciences will post ($2.18) earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Paloma Partners Management Co purchased a new position in shares of Calithera Biosciences during the second quarter worth $150,000. GSA Capital Partners LLP raised its position in shares of Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock worth $162,000 after buying an additional 9,000 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Calithera Biosciences during the first quarter worth $218,000. Franklin Street Advisors Inc. NC raised its position in shares of Calithera Biosciences by 18.6% in the third quarter. Franklin Street Advisors Inc. NC now owns 100,000 shares of the company’s stock worth $325,000 after buying an additional 15,700 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Calithera Biosciences by 6.9% in the first quarter. Geode Capital Management LLC now owns 66,250 shares of the company’s stock worth $376,000 after buying an additional 4,286 shares during the last quarter. 48.37% of the stock is currently owned by institutional investors.

Calithera Biosciences Company Profile

Related posts

Leave a Comment